Interneuron Redux Settlement Offer Denied Due To Valuation "Uncertainty"
Executive Summary
The unpredictability of Interneuron's future cash-flow served as a basis of Eastern District of Pennsylvania Judge Louis Bechtle's Sept. 27 decision to deny the company's proposed settlement for diet drug Redux medical claims.
You may also be interested in...
AHP Redux Litigation Roster Adds Fraud Suit From Interneuron
American Home Products' lingering Redux liability now includes a fraud lawsuit brought by its former marketing partner Interneuron.
AHP Redux Litigation Roster Adds Fraud Suit From Interneuron
American Home Products' lingering Redux liability now includes a fraud lawsuit brought by its former marketing partner Interneuron.
AHP Redux Settlement Doubles Cash Payments For Use Of Drug Over 60 Days
Patients who used American Home Products' Redux or Pondimin for more than 60 days would be eligible to receive a cash payment of $6,000 if an echocardiogram shows heart valve regurgitation, while those who used the drugs for 60 days or less could receive $3,000, under a settlement proposed by AHP.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: